Objectives: A recent phase III trial showed that patients with advanced non-small cell lung
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …

Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …

BACKGROUND: Lung cancer is the most common non-skin cancer and the leading cause of
cancer death among men and women in North America. More than half of all patients …

Objective: Assess the budgetary impact of adding erlotinib for maintenance therapy (MTx) in
advanced non-small cell lung cancer (NSCLC) from a US health plan perspective. Methods …

Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …

Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …

6531 Background: Previously we have shown that the incremental cost effectiveness ratio
(ICER) of erlotinib, in unselected patients with advanced non-small cell lung cancer …

Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …

Objectives To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or
afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial …

Objective: A cost-minimisation and budget impact analysis of erlotinib versus docetaxel or
pemetrexed as second-line treatment for advanced non-small-cell lung cancer (NSCLC) …